var data={"title":"Propofol: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Propofol: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6857?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=propofol-patient-drug-information\" class=\"drug drug_patient\">see &quot;Propofol: Patient drug information&quot;</a> and <a href=\"topic.htm?path=propofol-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Propofol: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F214584\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Anesthesia S/I-40;</li>\n      <li>Anesthesia S/I-40A;</li>\n      <li>Anesthesia S/I-40H;</li>\n      <li>Anesthesia S/I-40S;</li>\n      <li>Anesthesia S/I-60;</li>\n      <li>Diprivan;</li>\n      <li>Fresenius Propoven</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F214585\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Diprivan;</li>\n      <li>PMS-Propofol;</li>\n      <li>Propofol Injection;</li>\n      <li>Propofol-II Injection</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F214628\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        General Anesthetic</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F214588\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">Consult local regulations and individual institutional policies and procedures. Dosage must be individualized based on total body weight and titrated to the desired clinical effect. Wait at least 3 to 5 minutes between dosage adjustments to clinically assess drug effects. Smaller doses are required when used with opioids; the following are general dosing guidelines (see &ldquo;Abbreviations, Acronyms, and Symbols&rdquo; for explanation of ASA-PS classes):</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>General anesthesia: Note:</b> Increase dose in patients with chronic alcoholism (Fassoulaki 1993); decrease dose with acutely intoxicated (alcoholic) patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Induction of general anesthesia:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Healthy adults, ASA-PS 1 or 2, &lt;55 years: IV: 2 to 2.5 mg/kg (~40 mg every 10 seconds until onset of induction)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Debilitated, ASA-PS 3 or 4: Refer to geriatric dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Maintenance of general anesthesia:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Healthy adults, ASA-PS 1 or 2, &lt;55 years:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">IV infusion: Initial: 100 to 200 mcg/kg/minute (or 6 to 12 mg/kg/<b>hour</b>) for 10 to 15 minutes; usual maintenance infusion rate: 50 to 100 mcg/kg/minute (or 3 to 6 mg/kg/<b>hour</b>) to optimize recovery time.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">IV intermittent bolus: 25 to 50 mg increments as needed</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Debilitated, ASA-PS 3 or 4: IV Infusion: Refer to geriatric dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Monitored anesthesia care sedation:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Healthy adults, ASA-PS 1 or 2, &lt;55 years: Slow IV infusion: 100 to 150 mcg/kg/minute (or 6 to 9 mg/kg/<b>hour</b>) for 3 to 5 minutes <b>or</b> slow injection: 0.5 mg/kg over 3 to 5 minutes followed by IV infusion of 25 to 75 mcg/kg/minute (or 1.5 to 4.5 mg/kg/<b>hour</b>) <b>or</b> incremental bolus doses: 10 mg or 20 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Debilitated or ASA-PS 3 or 4 patients: Use 80% of healthy adult dose</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>ICU sedation in intubated mechanically-ventilated patients:</b> Avoid rapid bolus injection; individualize dose and titrate to response.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Continuous infusion:</i> Initial: 5 mcg/kg/minute (or 0.3 mg/kg/<b>hour</b>); increase by 5 to 10 mcg/kg/minute (or 0.3 to 0.6 mg/kg/<b>hour</b>) every 5 to 10 minutes until desired sedation level is achieved; usual maintenance: 5 to 50 mcg/kg/minute (or 0.3 to 3 mg/kg/<b>hour</b>); reduce dose after adequate sedation established and adjust to response (eg, evaluate frequently to use minimum dose for sedation). Daily interruption with retitration or a light target level of sedation is recommended to minimize prolonged sedative effects (Barr 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Elderly, debilitated, or ASA-PS 3 or 4 patients: Refer to geriatric dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Postoperative nausea and vomiting (PONV), rescue therapy (off-label use):</b> IV: 15 to 20 mg, may be repeated (SAA [Gan 2014]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Status epilepticus, refractory (off-label use):</b> IV: <b>Note:</b> Mechanical ventilation and cardiovascular monitoring required; titrate dose to cessation of electrographic seizures or burst suppression (NCS [Brophy, 2012]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Neurocritical Care Society recommendations</i> (NCS [Brophy 2012]):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Loading dose: 1 to 2 mg/kg with initiation of a continuous infusion.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Continuous infusion: Initial: 20 mcg/kg/minute (1.2 mg/kg/<b>hour</b>). If the patient experiences breakthrough status epilepticus while on continuous infusion, increase infusion rate by 5 to 10 mcg/kg/minute (0.3 to 0.6 mg/kg/<b>hour</b>) every 5 minutes (may also administer a 1 mg/kg bolus dose with continuous infusion titration); dosage range: 30 to 200 mcg/kg/minute (1.8 to 12 mg/kg/<b>hour</b>). <b>Note:</b> Use caution with doses &gt;80 mcg/kg/minute (&gt;4.8 mg/kg/<b>hour</b>) for &gt;48 hours. Prior to withdrawal, a period of at least 24 to 48 hours of electrographic control is recommended; withdraw gradually to prevent recurrent status epilepticus.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F214606\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=propofol-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Propofol: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">Consult local regulations and individual institutional policies and procedures. Dosage must be individualized based on total body weight and titrated to the desired clinical effect. Wait at least 3 to 5 minutes between dosage adjustments to clinically assess drug effects. Smaller doses are required when used with opioids; the following are general dosing guidelines (see &ldquo;Abbreviations, Acronyms, and Symbols&rdquo; for explanation of ASA-PS classes):</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>General anesthesia:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Induction of general anesthesia:</i> IV: Healthy children 3 to 16 years, ASA-PS 1 or 2: 2.5 to 3.5 mg/kg over 20 to 30 seconds; use a lower dose for children ASA-PS 3 or 4</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Maintenance of general anesthesia:</i> IV infusion: Healthy children 2 months to 16 years, ASA-PS 1 or 2: 125 to 300 mcg/kg/minute (or 7.5 to 18 mg/kg/<b>hour</b>); after 30 minutes, if clinical signs of light anesthesia are absent, decrease the infusion rate. Children &le;5 years may require larger infusion rates compared to older children.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Status epilepticus, refractory (off-label use):</b> IV: <b>Note:</b> Mechanical ventilation and cardiovascular monitoring required; titrate dose to cessation of electrographic seizures or burst suppression (NCS [Brophy 2012]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Neurocritical Care Society recommendations</i> (NCS [Brophy 2012]):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Loading dose: 1 to 2 mg/kg with initiation of a continuous infusion.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Continuous infusion: Initial: 20 mcg/kg/minute (1.2 mg/kg/<b>hour</b>). If the patient experiences breakthrough status epilepticus while on continuous infusion, increase infusion rate by 5 to 10 mcg/kg/minute (0.3 to 0.6 mg/kg/<b>hour</b>) every 5 minutes (may also administer a 1 mg/kg bolus dose with continuous infusion titration); dosage range: 30 to 200 mcg/kg/minute (1.8 to 12 mg/kg/<b>hour</b>). <b>Note:</b> Use caution with doses &gt;80 mcg/kg/minute (&gt;4.8 mg/kg/<b>hour</b>) for &gt;48 hours. Prior to withdrawal, a period of at least 24 to 48 hours of electrographic control is recommended; withdraw gradually to prevent recurrent status epilepticus.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F214589\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Consult local regulations and individual institutional policies and procedures. Dosage must be individualized based on total body weight and titrated to the desired clinical effect. Wait at least 3 to 5 minutes between dosage adjustments to clinically assess drug effects. Smaller doses are required when used with opioids; the following are general dosing guidelines (see &ldquo;Abbreviations, Acronyms, and Symbols&rdquo; for explanation of ASA-PS classes): </p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">\n      <b>General anesthesia: Note: </b> Increase dose in patients with chronic alcoholism (Fassoulaki, 1993); decrease dose with acutely intoxicated (alcoholic) patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <i>Induction of general anesthesia:</i> Elderly, debilitated, ASA-PS 3 or 4: IV: 1 to 1.5 mg/kg (~20 mg every 10 seconds until onset of induction)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <i>Maintenance of general anesthesia:</i> Elderly, debilitated, ASA-PS 3 or 4: IV infusion: 50 to 100 mcg/kg/minute (or 3 to 6 mg/kg/<b>hour</b>) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Monitored anesthesia care sedation: </b> Elderly, debilitated, ASA-PS 3 or 4: IV: Use 80% of healthy adult dose</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>ICU sedation in intubated mechanically-ventilated patients:</b> Avoid rapid bolus injection; individualize dose and titrate to response: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <i>Continuous infusion:</i> Elderly, debilitated, ASA-PS 3 or 4: Use 80% of healthy adult dose; reduce dose after adequate sedation established and adjust to response (eg, evaluate frequently to use minimum dose for sedation). Daily interruption with retitration or a light target level of sedation is recommended to minimize prolonged sedative effects (Barr 2013).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13135189\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">No dosage adjustment necessary.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13135190\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">No dosage adjustment necessary.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F214558\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Emulsion, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Diprivan: 100 mg/10 mL (10 mL [DSC]); 200 mg/20 mL (20 mL); 500 mg/50 mL (50 mL); 1000 mg/100 mL (100 mL) [contains edetate disodium, egg phospholipids (egg lecithin), glycerin, soybean oil]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 1000 mg/100 mL (100 mL); 200 mg/20 mL (20 mL); 500 mg/50 mL (50 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Emulsion, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Fresenius Propoven: 200 mg/20 mL (20 mL); 500 mg/50 mL (50 mL); 1000 mg/100 mL (100 mL) [contains egg phosphatides, soybean oil]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 1000 mg/100 mL (100 mL); 200 mg/20 mL (20 mL); 500 mg/50 mL (50 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Kit, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Anesthesia S/I-40: 200 mg/20 mL [contains edetate disodium, egg phospholipids (egg lecithin), soybean oil]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Anesthesia S/I-60: 200 mg/20 mL [contains edetate disodium, egg phospholipids (egg lecithin), soybean oil]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Anesthesia S/I-40A: 200 mg/20 mL [contains egg phospholipids (egg lecithin), sodium benzoate, soybean oil]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Anesthesia S/I-40H: 200 mg/20 mL [contains egg phospholipids (egg lecithin), sodium benzoate, soybean oil]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Anesthesia S/I-40S: 200 mg/20 mL [contains egg phospholipids (egg lecithin), sodium metabisulfite, soybean oil]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Prefilled Syringe, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 200 mg/20 mL (20 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F214542\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F214560\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">IV: Administer IVP or by continuous IV infusion. Consult local regulations and individual institutional policies and procedures. Strict aseptic technique must be maintained in handling although a preservative has been added. Do not use if contamination is suspected. Do not administer through the same IV catheter with blood or plasma. Tubing and any unused portions of propofol vials should be discarded after 12 hours.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">To reduce pain associated with injection, use larger veins of forearm or antecubital fossa; lidocaine IV (1 mL of a 1% solution) may also be used prior to administration or it may be added to propofol immediately before administration in a quantity not to exceed 20 mg lidocaine per 200 mg propofol. Do not use filter &lt;5 micron for administration.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F214559\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Induction of anesthesia in patients &ge;3 years of age; maintenance of anesthesia in patients &gt;2 months of age; in adults, for monitored anesthesia care sedation during procedures; in adults, for sedation in intubated, mechanically-ventilated ICU patients</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">\n      <b>Note:</b> Consult local regulations and individual institutional policies and procedures.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27235450\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Postoperative nausea and vomiting (PONV), rescue therapy; Status epilepticus, refractory</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F214636\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Diprivan may be confused with Diflucan, Ditropan</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Propofol may be confused with fospropofol</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Propofol may be confused with bupivacaine (liposomal) due to similar white, milky appearance.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error. </p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Administration issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Propofol may be confused with bupivacaine liposome injectable suspension (Exparel) in operating rooms and other surgical areas due to their similar white, milky appearance especially when prepared in syringes. Bupivacaine liposome injectable suspension (Exparel) is intended only for administration via infiltration into the surgical site (and <b>not </b>for systemic use). Confusion with propofol may lead to accidental intravenous administration of Exparel instead of the intended propofol. Therefore, to avoid potential confusion ISMP recommends that all vials be separated when stocked in common areas and all prepared syringes be labeled. </p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F214549\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Hypotension (adults: 3% to 26%; children: 17%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Involuntary body movements (children: 17%; adults: 3% to 10%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Burning sensation at injection site (adults: &le;18%; children: &le;10%), pain at injection site (includes stinging; adults: &le;18%; children: &le;10%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Apnea (30 to 60 seconds duration: adults: 24%, children: 10%;  &gt;60 seconds duration: adults: 12%, children: 5%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Hypertension (children: 8%), bradycardia (1% to 3%), cardiac arrhythmia (1% to 3%), low cardiac output (1% to 3%; concurrent opioid use increases incidence), tachycardia (1% to 3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Skin rash (children: 5%; adults: 1% to 3%), pruritus (1% to 3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Hypertriglyceridemia (3% to 10%), respiratory acidosis (during weaning; 3% to 10%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Agitation, amblyopia, anaphylaxis, anaphylactoid reaction, anticholinergic syndrome, asystole, atrial arrhythmia, atrial premature contractions, bigeminy, chills, cloudy urine, cough, decreased lung function, delirium, dizziness, drowsiness, fever, flushing, hair discoloration (green), hemorrhage, hypertonia, hypomagnesemia, hypoxia, infusion-related reaction (propofol-related infusion syndrome), infusion site reaction (including pain, swelling, blisters and/or tissue necrosis following accidental extravasation), laryngospasm, leukocytosis, limb pain, loss of consciousness (postoperative; with or without increased muscle tone), myalgia, myoclonus (rarely including seizure and opisthotonos), nail discoloration (nailbeds green), nausea, pancreatitis, paresthesia, phlebitis, pulmonary edema, rhabdomyolysis, sialorrhea, syncope, thrombosis, urine discoloration (green), ventricular premature contractions, visual disturbance, wheezing</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F214563\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to propofol or any component of the formulation; hypersensitivity to eggs, egg products, soybeans, or soy products; when general anesthesia or sedation is contraindicated.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note:</b> Although the manufacturer&rsquo;s labeling lists egg allergy as a contraindication, available studies (mostly retrospective) have suggested that propofol may be used safely in certain egg-allergic patients without a history of anaphylaxis related to egg ingestion (AAAI [Lieberman 2015]; Asserhoj 2016; Dziedzic 2016; Murphy 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Additional contraindication (not in US labeling): Hypersensitivity to lipid emulsions; sedation of children &le;18 years of age receiving intensive care.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F214546\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anaphylaxis/hypersensitivity reactions: May rarely cause hypersensitivity, anaphylaxis, anaphylactoid reactions, angioedema, bronchospasm, and erythema; medications for the treatment of hypersensitivity reactions should be available for immediate use. Use with caution in patients with history of hypersensitivity/anaphylactic reaction to peanuts; a low risk of crossreactivity between soy and peanuts may exist. According to the manufacturer, use is contraindicated in patients who are hypersensitive to eggs, egg products, soybeans, or soy products. However, available studies (mostly retrospective) have suggested that propofol may be used safely in certain egg-allergic patients without a history of anaphylaxis related to egg ingestion (AAAI [Lieberman 2015]; Asserhoj 2016; Dziedzic 2016; Murphy 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; ECG effects: In most cases, propofol does not significantly affect the QT interval (Staikou 2014). However, prolongation of the QT interval, usually within normal limits, has occurred in case reports and small prospective studies and may be dose dependent (Hume-Smith 2008; Kim 2008; McConachie 1989; Saarnivaara 1990; Saarnivaara 1993; Sakabe 2002). Shortening of the QT interval has also occurred (Erdil 2009; Tanskanen 2002).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypertriglyceridemia: Because propofol is formulated within a 10% fat emulsion, hypertriglyceridemia is an expected side effect. Patients who develop hypertriglyceridemia (eg, &gt;500 mg/dL) are at risk of developing pancreatitis. Serum triglyceride levels should be obtained prior to initiation of therapy and every 3 to 7 days thereafter. Monitoring of serum triglycerides should especially be considered with therapy &gt;48 hours with doses exceeding 50 mcg/kg/minute (Devlin 2005). An alternative sedative agent should be employed if significant hypertriglyceridemia occurs. Use with caution in patients with preexisting hyperlipidemia as evidenced by increased serum triglyceride levels or serum turbidity.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypotension: The major cardiovascular effect of propofol is hypotension especially if patient is hypovolemic or if bolus dosing is used. Hypotension may be substantial with a reduction in mean arterial pressure occasionally exceeding 30%. Use with caution in patients who are hemodynamically unstable, hypovolemic, or have abnormally low vascular tone (eg, sepsis).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Injection-site reaction: Transient local pain may occur during IV injection; lidocaine 1% solution may be administered prior to administration or may be added to propofol immediately prior to administration to reduce pain associated with injection (see Administration).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Myoclonus: Perioperative myoclonus (eg, convulsions and opisthotonos) has occurred with administration.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Propofol-related infusion syndrome (PRIS): PRIS is a serious side effect with a high mortality rate (up to 33%) characterized by dysrhythmia (eg, bradycardia or tachycardia), heart failure, hyperkalemia, lipemia, metabolic acidosis, and/or rhabdomyolysis or myoglobinuria with subsequent renal failure. Risk factors include poor oxygen delivery, sepsis, serious cerebral injury, and the administration of high doses of propofol (usually doses &gt;83 mcg/kg/minute or &gt;5 mg/kg/hour for &gt;48 hours), but has also been reported following large dose, short-term infusions during surgical anesthesia. PRIS has also been reported with lower-dose infusions (Chukwuemeka 2006; Merz 2006). The onset of the syndrome is rapid, occurring within 4 days of initiation. The mechanism of the syndrome has yet to be determined. Alternate sedative therapy should be considered for patients with escalating doses of vasopressors or inotropes, when cardiac failure occurs during high-dose propofol infusion, when metabolic acidosis is observed, or in whom lengthy and/or high-dose sedation is needed (Barr 2013; Corbett 2008).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disease: Use with caution in patients with severe cardiac disease (ejection fraction &lt;50%) or hypotension; may have more profound adverse cardiovascular responses to propofol. In a scientific statement from the American Heart Association, propofol has been determined to be an agent that may exacerbate underlying myocardial dysfunction (magnitude: moderate) (AHA [Page 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Increased intracranial pressure: Use with caution in patients with increased intracranial pressure or impaired cerebral circulation; substantial decreases in mean arterial pressure and subsequent decreases in cerebral perfusion pressure may occur; consider continuous infusion or administer as a slow bolus.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Infection risk: Propofol vials and prefilled syringes have the potential to support the growth of various microorganisms despite product additives intended to suppress microbial growth. To limit the potential for contamination, strictly adhere to recommendations in product labeling for handling and administering propofol.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pancreatitis: Use with caution in patients with preexisting pancreatitis; use of propofol may exacerbate this condition.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Respiratory disease: Use with caution in patients with respiratory disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Seizure disorder: Use with caution in patients with a history of epilepsy or seizures; seizure may occur during recovery phase.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Opioids: Concomitant use may lead to increased sedative or anesthetic effects of propofol, more pronounced decreases in systolic, diastolic, and mean arterial pressures and cardiac output; lower doses of propofol may be needed. In addition, fentanyl may cause serious bradycardia when used with propofol in pediatric patients. Alfentanil use with propofol has precipitated seizure activity in patients without any history of epilepsy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; ASA-PS (American Society of Anesthesiologists - Physical Status) 3/4 patients: Use a lower induction dose, a slower maintenance rate of administration, and avoid rapidly delivered boluses in ASA-PS 3/4 patients to reduce the incidence of unwanted cardiorespiratory depressive events.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Debilitated patients: Use a lower induction dose, a slower maintenance rate of administration, and avoid rapidly delivered boluses in debilitated patients to reduce the incidence of unwanted cardiorespiratory depressive events.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Use a lower induction dose, a slower maintenance rate of administration, and avoid rapidly delivered boluses in elderly patients to reduce the incidence of unwanted cardiorespiratory depressive events.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric neurotoxicity: In pediatric and neonatal patients &lt;3 years and patients in third trimester of pregnancy (ie, times of rapid brain growth and synaptogenesis), the repeated or lengthy exposure to sedatives or anesthetics during surgery/procedures may have detrimental effects on child or fetal brain development and may contribute to various cognitive and behavioral problems. Epidemiological studies in humans have reported various cognitive and behavioral problems including neurodevelopmental delay (and related diagnoses), learning disabilities, and ADHD. Human clinical data suggest that single, relatively short exposures are not likely to have similar negative effects. No specific anesthetic/sedative has been found to be safer. For elective procedures, risk vs benefits should be evaluated and discussed with parents/caregivers/patients; critical surgeries should not be delayed (FDA 2016).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Benzyl alcohol and derivatives: Some dosage forms may contain benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP [&quot;Inactive&quot; 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol with caution in neonates. See manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Edetate disodium: Some formulations contain edetate disodium which may lead to decreased zinc levels in patients with prolonged therapy (&gt;5 days) or a predisposition to zinc deficiency (eg, burns, diarrhea, or sepsis). A holiday from propofol infusion should take place after 5 days of therapy to allow for evaluation and necessary replacement of zinc.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Sulfites: Some formulations may contain sulfites.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Abrupt discontinuation: Avoid abrupt discontinuation prior to weaning or daily wake up assessments. Abrupt discontinuation can result in rapid awakening, anxiety, agitation, and resistance to mechanical ventilation; wean the infusion rate so the patient awakens slowly. Discontinue opioids and paralytic agents prior to weaning. Long-term infusions can result in some tolerance; taper propofol infusions to prevent withdrawal.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Analgesic supplementation: Propofol lacks analgesic properties; pain management requires specific use of analgesic agents, at effective dosages, propofol must be titrated separately from the analgesic agent.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Experienced personnel: Use requires careful patient monitoring, should only be used by experienced personnel who are not actively engaged in the procedure or surgery. If used in a nonintubated and/or nonmechanically ventilated patient, qualified personnel and appropriate equipment for rapid institution of respiratory and/or cardiovascular support must be immediately available. Use to induce moderate (conscious) sedation in patients warrants monitoring equivalent to that seen with deep anesthesia. Consult local regulations and individual institutional policies and procedures.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F214621\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP1A2 (minor), CYP2A6 (minor), CYP2B6 (major), CYP2C19 (minor), CYP2C9 (minor), CYP2D6 (minor), CYP2E1 (minor), CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> CYP2C9 (weak), CYP2E1 (weak), CYP3A4 (weak)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F214551\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9826&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alfentanil: May enhance the adverse/toxic effect of Propofol. Specifically the development of opisthotonus (severe hyperextension and spasticity resulting in arching or bridging position) and/or tonic clonic seizures.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alfuzosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, blood pressure lowering medications should be withheld for 24 hours prior to amifostine administration. If blood pressure lowering therapy cannot be withheld, amifostine should not be administered.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antipsychotic Agents (Second Generation [Atypical]): Blood Pressure Lowering Agents may enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Barbiturates: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Benperidol: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blood Pressure Lowering Agents: May enhance the hypotensive effect of Hypotension-Associated Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromopride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol. Bromperidol may diminish the hypotensive effect of Blood Pressure Lowering Agents. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Initiate buprenorphine patches (Butrans brand) at 5 mcg/hr in adults when used with other CNS depressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cannabis: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chlormethiazole: May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chlorphenesin Carbamate: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dimethindene (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Doxylamine: May enhance the CNS depressant effect of CNS Depressants. Management: The manufacturer of Diclegis (doxylamine/pyridoxine), intended for use in pregnancy, specifically states that use with other CNS depressants is  not recommended.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dronabinol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">EPHEDrine (Systemic): Propofol may enhance the therapeutic effect of EPHEDrine (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Flibanserin: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Flibanserin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Flunitrazepam: CNS Depressants may enhance the CNS depressant effect of Flunitrazepam. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Hypotensive Properties): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HYDROcodone: CNS Depressants may enhance the CNS depressant effect of HYDROcodone.  Management: Avoid concomitant use of hydrocodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypotension-Associated Agents: Blood Pressure Lowering Agents may enhance the hypotensive effect of Hypotension-Associated Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Kava Kava: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Levodopa: Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lofexidine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Patients on lomitapide 5 mg/day may continue that dose. Patients taking lomitapide 10 mg/day or more should decrease the lomitapide dose by half. The lomitapide dose may then be titrated up to a max adult dose of 30 mg/day.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MetyroSINE: CNS Depressants may enhance the sedative effect of MetyroSINE. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Midazolam: May increase the serum concentration of Propofol. Propofol may increase the serum concentration of Midazolam.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying). Management: Though the drugs listed here have uncertain QT-prolonging effects, they all have some possible association with QT prolongation and should generally be avoided when possible.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Minocycline: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nabilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Naftopidil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicergoline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">NiMODipine: CYP3A4 Inhibitors (Weak) may increase the serum concentration of NiMODipine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Opioid Analgesics: CNS Depressants may enhance the CNS depressant effect of Opioid Analgesics.  Management: Avoid concomitant use of opioid analgesics and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Orphenadrine: CNS Depressants may enhance the CNS depressant effect of Orphenadrine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oxomemazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OxyCODONE: CNS Depressants may enhance the CNS depressant effect of OxyCODONE.  Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Piribedil: CNS Depressants may enhance the CNS depressant effect of Piribedil. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Highest Risk): QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Moderate Risk): QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">RifAMPin: May enhance the hypotensive effect of Propofol. Management: Note that use of propofol in a patient who has been taking rifampin may result in clinically significant hypotension.  If possible, avoid use of this combination.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ropivacaine: Propofol may increase the serum concentration of Ropivacaine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rufinamide: May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Suvorexant: CNS Depressants may enhance the CNS depressant effect of Suvorexant.  Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary.  Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tapentadol: May enhance the CNS depressant effect of CNS Depressants. Management: Avoid concomitant use of tapentadol and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetrahydrocannabinol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thalidomide: CNS Depressants may enhance the CNS depressant effect of Thalidomide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thiotepa: May increase the serum concentration of CYP2B6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trimeprazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Valproate Products: May enhance the therapeutic effect of Propofol.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for  men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F214579\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Edetate disodium, an ingredient of propofol emulsion, may lead to decreased zinc levels in patients on prolonged therapy (&gt;5 days) or those predisposed to deficiency (burns, diarrhea, and/or major sepsis). Management: Zinc replacement therapy may be needed.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F214566\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;\">Propofol crosses the placenta and may be associated with neonatal CNS and respiratory depression. Propofol is not recommended by the manufacturer for obstetrics, including cesarean section deliveries.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Based on animal data, repeated or prolonged use of general anesthetic and sedation medications that block N-methyl-D-aspartate (NMDA) receptors and/or potentiate gamma-aminobutyric acid (GABA) activity may affect brain development. Human fetuses may be most vulnerable during the third trimester. Until additional information is available, the benefits and risks of maternal treatment with propofol during pregnancy should be evaluated, especially for procedures lasting more than 3 hours. The ACOG recommends that pregnant women should not be denied medically indicated surgery or procedures, regardless of trimester. If the procedure is elective, it should be delayed until after delivery (ACOG 2011).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20619295\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Propofol is present in breast milk. Breastfeeding is not recommended by the manufacturer. A green discoloration to the breast milk was noted in a woman following administration of propofol during surgery for removal of an ectopic pregnancy. Although other medications were also administered, propofol was detected in the milk and assumed to be the cause; resolution of this effect occurred within 48 hours after surgery (Birkholz 2009).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F214567\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Propofol is formulated in an oil-in-water emulsion. If on parenteral nutrition, may need to adjust the amount of lipid infused. Propofol emulsion contains 1.1 kcal/mL. Soybean fat emulsion is used as a vehicle for propofol. Formulations also contain egg phosphatide and glycerol.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F214556\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Cardiac monitor, blood pressure, oxygen saturation (during monitored anesthesia care sedation), arterial blood gas (with prolonged infusions). With prolonged infusions (eg, ICU sedation), monitor for signs and symptoms of propofol-related infusion syndrome (PRIS): Metabolic acidosis, hyperkalemia, rhabdomyolysis or elevated CPK, hepatomegaly, and progression of cardiac and renal failure.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">ICU sedation: Assess and adjust sedation according to scoring system (Richmond Agitation-Sedation Scale [RASS] or Sedation-Agitation Scale [SAS]) (SCCM [Barr 2013]); assess CNS function daily. Serum triglyceride levels should be obtained prior to initiation of therapy and every 3-7 days thereafter, especially if receiving for &gt;48 hours with doses exceeding 50 mcg/kg/minute (Devlin, 2005); use intravenous port opposite propofol infusion or temporarily suspend infusion and flush port prior to blood draw.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Diprivan: Monitor zinc levels in patients predisposed to deficiency (burns, diarrhea, major sepsis) or after 5 days of treatment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F214545\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Propofol is a short-acting, lipophilic intravenous general anesthetic. The drug is unrelated to any of the currently used barbiturate, opioid, benzodiazepine, arylcyclohexylamine, or imidazole intravenous anesthetic agents. Propofol causes global CNS depression, presumably through agonism of GABA<sub>A</sub> receptors and perhaps reduced glutamatergic activity through NMDA receptor blockade. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F214562\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: Anesthetic: Bolus infusion (dose dependent): 9 to 51 seconds (average 30 seconds)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Duration: 3 to 10 minutes depending on the dose, rate and duration of administration; with prolonged use (eg, 10 days ICU sedation), propofol accumulates in tissues and redistributes into plasma when the drug is discontinued, so that the time to awakening (duration of action) is increased; however, if dose is titrated on a daily basis, so that the minimum effective dose is utilized, time to awakening may be within 10 to 15 minutes even after prolonged use</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: Large volume of distribution; highly lipophilic ; V<sub>d</sub>:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children 4 to 12 years: 5 to 10 L/kg </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adults: 2 to 10 L/kg; after a 10-day infusion, V<sub>d</sub> approaches 60 L/kg; decreased in the elderly</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: 97% to 99% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic to water-soluble sulfate and glucuronide conjugates (~50%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: Biphasic: Initial: 40 minutes; Terminal: 4 to 7 hours (after 10-day infusion, may be up to 1 to 3 days) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (~88% as metabolites, 40% as glucuronide metabolite); feces (&lt;2%) </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323734\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Emulsion</b> (Diprivan Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg/20 mL (20 mL): $2.88</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg/50 mL (50 mL): $7.20</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1000 mg/100 mL (100 mL): $14.40</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Emulsion</b> (Propofol Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg/20 mL (20 mL): $1.90</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg/50 mL (50 mL): $4.66</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1000 mg/100 mL (100 mL): $9.26</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Prefilled Syringe</b> (Propofol Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg/20 mL (20 mL): $9.35</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F214568\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Anepol (KR, TH);</li>\n      <li>Anesia (LK);</li>\n      <li>Anesvan (TH);</li>\n      <li>Aquafol (KR);</li>\n      <li>Diprivan (AE, AR, AT, AU, BB, BE, BF, BG, BH, BJ, BM, BR, BS, BZ, CI, CL, CN, CO, CR, CU, CY, CZ, DE, DK, DO, EE, EG, ES, ET, FI, FR, GB, GH, GM, GN, GR, GT, GY, HK, HN, HR, HU, ID, IE, IL, IN, IQ, IR, IT, JM, JO, KE, KW, LB, LR, LU, LV, LY, MA, ML, MR, MT, MU, MW, MX, MY, NE, NG, NI, NL, NZ, OM, PA, PE, PH, PK, PL, PR, PT, QA, RU, SA, SC, SD, SE, SI, SK, SL, SN, SR, SV, SY, TN, TR, TT, TW, TZ, UG, UY, VE, VN, YE, ZA, ZM, ZW);</li>\n      <li>Diprofen (TW);</li>\n      <li>Diprofol (IL);</li>\n      <li>Disoprivan (CH, HR);</li>\n      <li>Dyprofol (UA);</li>\n      <li>Dypryvan (UA);</li>\n      <li>Emifol (BD);</li>\n      <li>Fresofol (AU, KR, MY, NZ, PH, TW);</li>\n      <li>Fresofol MCT/LCT (HK, ID, TH);</li>\n      <li>Gobbifol (AR, PY);</li>\n      <li>Indofol (MX);</li>\n      <li>Lexofol (PH);</li>\n      <li>Lipofol (TW);</li>\n      <li>Lipuro (PH);</li>\n      <li>Neorof (ET, PH);</li>\n      <li>Nirfol (LK, ZW);</li>\n      <li>Pofol (BD, KR, TH);</li>\n      <li>Proanes (ID);</li>\n      <li>Profast (RO);</li>\n      <li>Profosol (PH);</li>\n      <li>Propofol-Lipuro (EC);</li>\n      <li>Propovan (LK, PY);</li>\n      <li>Propoven (EE, IE, LV);</li>\n      <li>Provive (AU, HK, KR, LB, NZ, QA, ZW);</li>\n      <li>Recofol (AE, BH, CH, CY, ES, HU, ID, IL, JO, MX, QA, SG, TH);</li>\n      <li>Recofol N (MT, SG);</li>\n      <li>Safol (ID);</li>\n      <li>Spiva with MCT-LCT (PH);</li>\n      <li>Trivam (ID);</li>\n      <li>Troyppofol (TZ);</li>\n      <li>Ufol (BD)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    ACOG Committee on Obstetric Practice. ACOG Committee Opinion No. 474: nonobstetric surgery during pregnancy. <i>Obstet Gynecol</i>. 2011;117:420-421. doi:10.1097/AOG.0b013e31820eede9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/propofol-drug-information/abstract-text/21252774/pubmed\" target=\"_blank\" id=\"21252774\">21252774</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/propofol-drug-information/abstract-text/11487763/pubmed\" target=\"_blank\" id=\"11487763\">11487763</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"26675952\"></a>Asserh&oslash;j LL, Mosbech H, Kr&oslash;igaard M, Garvey LH. No evidence for contraindications to the use of propofol in adults allergic to egg, soy or peanut.<i> Br J Anaesth</i>. 2016;116(1):77-82.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/propofol-drug-information/abstract-text/26675952/pubmed\" target=\"_blank\" id=\"26675952\">26675952</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Barr J, Fraser GL, Puntillo K, et al, &ldquo;Clinical Practice Guidelines for the Management of Pain, Agitation, and Delirium in Adult Patients in the Intensive Care Unit,&rdquo; <i>Crit Care Med</i>, 2013, 41(1):263-306.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/propofol-drug-information/abstract-text/23269131/pubmed\" target=\"_blank\" id=\"23269131\">23269131</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bedforth NM and Lockey DJ, &ldquo;Raynaud's Syndrome Following Intravenous Induction of Anaesthesia,&rdquo; <i>Anaesthesia</i>, 1995, 50(3):248-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/propofol-drug-information/abstract-text/7717494/pubmed\" target=\"_blank\" id=\"7717494\">7717494</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bennett SN, McNeil MM, Bland LA, et al, &ldquo;Postoperative Infections Traced to Contamination of an Intravenous Anesthetic, Propofol,&rdquo; <i>N Engl J Med</i>, 1995, 333(3):147-54.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/propofol-drug-information/abstract-text/7791816/pubmed\" target=\"_blank\" id=\"7791816\">7791816</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Birkholz T, Eckardt G, Renner S, et al. Green breast milk after propofol administration. <i>Anesthesiology</i>. 2009;111(5):1168-1169.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/propofol-drug-information/abstract-text/19858894 /pubmed\" target=\"_blank\" id=\"19858894 \">19858894 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bradley AED, Tober KES, and Brown RE, &ldquo;Use of Propofol in Patients with Food Allergies,&rdquo; <i>Anaesthesia</i>, 2008, 63(4):433-45.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/propofol-drug-information/abstract-text/18336502/pubmed\" target=\"_blank\" id=\"18336502\">18336502</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Brophy GM, Bell R, Claassen J, et al; Neurocritical Care Society Status Epilepticus Guideline Writing Committee. Guidelines for the evaluation and management of status epilepticus. <i>Neurocrit Care</i>. 2012;17(1):3-23.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/propofol-drug-information/abstract-text/22528274/pubmed\" target=\"_blank\" id=\"22528274\">22528274</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Burow BK, Johnson ME, and Packer DL, &ldquo;Metabolic Acidosis Associated With Propofol in the Absence of Other Causative Factors,&rdquo; <i>Anesthesiology</i>, 2004, 101(1):239-41.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/propofol-drug-information/abstract-text/15220796/pubmed\" target=\"_blank\" id=\"15220796\">15220796</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cawley MJ, Guse TM, Laroia A, et al, &ldquo;Propofol Withdrawal Syndrome in an Adult Patient With Thermal Injury,&rdquo; <i>Pharmacotherapy</i>, 2003, 23(7):933-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/propofol-drug-information/abstract-text/12885106/pubmed\" target=\"_blank\" id=\"12885106\">12885106</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol&mdash;United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/propofol-drug-information/abstract-text/6810084/pubmed\" target=\"_blank\" id=\"6810084\">6810084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chukwuemeka A, Ko R, and Ralph-Edwards A, &ldquo;Short-term Low-Dose Propofol Anaesthesia Associated with Severe Metabolic Acidosis,&rdquo; <i>Anaesth Intensive Care</i>, 2006, 34(5):651-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/propofol-drug-information/abstract-text/17061643/pubmed\" target=\"_blank\" id=\"17061643\">17061643</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Claassen J, Hirsch LJ, Emerson RG, et al, &ldquo;Treatment of Refractory Status Epilepticus With Pentobarbital, Propofol, or Midazolam: A Systematic Review,&rdquo; <i>Epilepsia</i>, 2002, 43(2):146-53.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/propofol-drug-information/abstract-text/11903460/pubmed\" target=\"_blank\" id=\"11903460\">11903460</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Corbett SM, Montoya ID, and Moore FA, &ldquo;Propofol-Related Infusion Syndrome in Intensive Care Patients,&rdquo; <i>Pharmacotherapy</i>, 2008, 28(2):250-58.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Devlin JW, Lau AK, and Tanios MA, &ldquo;Propofol-Associated Hypertriglyceridemia and Pancreatitis in the Intensive Care Unit: An Analysis of Frequency and Risk Factors,&rdquo; <i>Pharmacotherapy</i>, 2005, 25(10):1348-52.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Diprivan (propofol) [prescribing information]. Lake Zurich: Fresenius Kabi USA, LLC; October 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Diprivan (propofol) [product monograph]. Toronto, Ontario, Canada: Aspen Pharmacare Canada Inc; August 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"27145556\"></a>Dziedzic A. Is Propofol Safe For Food Allergy Patients? A Review of the Evidence. <i>SAAD Dig</i>. 2016;32:23-27.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/propofol-drug-information/abstract-text/27145556/pubmed\" target=\"_blank\" id=\"27145556\">27145556</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Erdil F, Demirbilek S, Begec Z, Ozturk E, Ersoy MO. Effects of propofol or etomidate on QT interval during electroconvulsive therapy. <i>J ECT</i>. 2009;25(3):174-177.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/propofol-drug-information/abstract-text/19225403/pubmed\" target=\"_blank\" id=\"19225403\">19225403</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    European Medicines Agency, &ldquo;Public Statement on the Allergenic Potency of Herbal Medicinal Products Containing Soya or Peanut Protein,&rdquo; London: European Medicines Agency, 2006. Available at http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/04/WC500089954.pdf. Accessed April 16, 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fassoulaki A, Farinotti R, Servin F, et al, &quot;Chronic Alcoholism Increases the Induction Dose of Propofol in Humans,&quot; <i>Anesth Analg</i>, 1993, 77(3):553-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/propofol-drug-information/abstract-text/8368555/pubmed\" target=\"_blank\" id=\"8368555\">8368555</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"24356162\"></a>Gan TJ, Diemunsch P, Habib AS, et al. Consensus guidelines for the management of postoperative nausea and vomiting. <i>Anesth Analg</i>. 2014;118(1):85-113.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/propofol-drug-information/abstract-text/24356162/pubmed\" target=\"_blank\" id=\"24356162\">24356162</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"10360853\"></a>Gan TJ, El-Molem H, Ray J, Glass PS. Patient-controlled antiemesis: a randomized, double-blind comparison of two doses of propofol versus placebo. <i>Anesthesiology</i>. 1999;90(6):1564-1570.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/propofol-drug-information/abstract-text/10360853/pubmed\" target=\"_blank\" id=\"10360853\">10360853</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gangineni K, Scase AE, and Fearn J, &ldquo;Propofol and Peanut Allergy,&rdquo; <i>Anaesthesia</i>, 2007, 62(11):1183-92.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/propofol-drug-information/abstract-text/17924915/pubmed\" target=\"_blank\" id=\"17924915\">17924915</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gross J, Bailey P, Connis R, et al, &ldquo;Practice Guidelines for Sedation and Analgesia by Non-Anesthesiologists. An Updated Report by the American Society of Anesthesiologist Task Force on Sedation and Analgesia by Nonanesthesiologists,&rdquo; Anesthesiology, 2002, 96(4):1004-17.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/propofol-drug-information/abstract-text/11964611/pubmed\" target=\"_blank\" id=\"11964611\">11964611</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hofer KN, McCarthy MW, Buck ML, et al, &ldquo;Possible Anaphylaxis After Propofol in a Child With Food Allergy,&quot; <i>Ann Pharmacother</i>, 2003; 37(3): 398&ndash;401.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/propofol-drug-information/abstract-text/12639172/pubmed\" target=\"_blank\" id=\"12639172\">12639172</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hume-Smith HV, Sanatani S, Lim J, Chau A, Whyte SD. The effect of propofol concentration on dispersion of myocardial repolarization in children. <i>Anesth Analg</i>. 2008;107(3):806-810.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/propofol-drug-information/abstract-text/18713888/pubmed\" target=\"_blank\" id=\"18713888\">18713888</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/propofol-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    K&auml;lvi&auml;inen R, &ldquo;Status Epilepticus Treatment Guidelines,&rdquo; <i>Epilepsia</i>, 2007, 48(Suppl 8):99-102.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/propofol-drug-information/abstract-text/18330014/pubmed\" target=\"_blank\" id=\"18330014\">18330014</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kim DH, Kweon TD, Nam SB, Han DW, Cho WY, Lee JS. Effects of target concentration infusion of propofol and tracheal intubation on QTc interval. <i>Anaesthesia</i>. 2008;63(10):1061-1064.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/propofol-drug-information/abstract-text/18717665/pubmed\" target=\"_blank\" id=\"18717665\">18717665</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kotani Y, Shimazawa M, Yoshimura S, et al, &ldquo;The Experimental and Clinical Pharmacology of Propofol, an Anesthetic Agent with Neuroprotective Properties,&rdquo; <i>CNS Neurosci Ther</i>, 2008, 14(2):95-106.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/propofol-drug-information/abstract-text/18482023/pubmed\" target=\"_blank\" id=\"18482023\">18482023</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kress JP and Hall JB, &ldquo;Sedation in the Mechanically Ventilated Patient,&rdquo; <i>Crit Care Med</i>, 2006, 34 (10):2541-46.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/propofol-drug-information/abstract-text/16932231/pubmed\" target=\"_blank\" id=\"16932231\">16932231</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kress JP, Pohlman AS, O'Connor MF, et al, &ldquo;Daily Interruption of Sedative Infusions in Critically Ill Patients Undergoing Mechanical Ventilation,&rdquo; <i>N Engl J Med</i>, 2000, 342(20):1471-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/propofol-drug-information/abstract-text/10816184/pubmed\" target=\"_blank\" id=\"10816184\">10816184</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"26505932\"></a>Lieberman P, Nicklas RA, Randolph C, et al. Anaphylaxis--a practice parameter update 2015. <i>Ann Allergy Asthma Immunol</i>. 2015;115(5):341-384.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/propofol-drug-information/abstract-text/26505932/pubmed\" target=\"_blank\" id=\"26505932\">26505932</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Liolios A, Guerit JM, Scholtes JL, et al, &ldquo;Propofol Infusion Syndrome Associated With Short-term Large-Dose Infusion During Surgical Anesthesia in an Adult,&rdquo; <i>Anesth Analg</i>, 2005, 100(6):1804-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/propofol-drug-information/abstract-text/15920217/pubmed\" target=\"_blank\" id=\"15920217\">15920217</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    McConachie I, Keaveny JP, Healy TE, Vohra S, Million L. Effect of anaesthesia on the QT interval. <i>Br J Anaesth</i>. 1989;63(5):558-560.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/propofol-drug-information/abstract-text/2605073/pubmed\" target=\"_blank\" id=\"2605073\">2605073</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    McCowan C and Marik P, &ldquo;Refractory Delirium Tremens Treated With Propofol: A Case Series,&rdquo; <i>Crit Care Med</i>, 2000, 28(6):1781-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/propofol-drug-information/abstract-text/10890619/pubmed\" target=\"_blank\" id=\"10890619\">10890619</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Meierkord H, Boon P, Engelsen B, et al, &ldquo;EFNS Guideline on the Management of Status Epilepticus in Adults,&rdquo; <i>Eur J Neurol</i>, 2010, 17(3):348-55.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/propofol-drug-information/abstract-text/20050893/pubmed\" target=\"_blank\" id=\"20050893\">20050893</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Merz TM, Regli B, Rothen HU, et al, &ldquo;Propofol Infusion Syndrome: A Fatal Case at a Low Infusion Rate,&rdquo; <i>Anesth Analg</i>, 2006, 103(4):1050.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/propofol-drug-information/abstract-text/17000843/pubmed\" target=\"_blank\" id=\"17000843\">17000843</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"21467558\"></a>Murphy A, Campbell DE, Baines D, et al. Allergic reactions to propofol in egg-allergic children. <i>Anesth Analg</i>. 2011;113(1):140-144.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/propofol-drug-information/abstract-text/21467558/pubmed\" target=\"_blank\" id=\"21467558\">21467558</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Page RL 2nd, O'Bryant CL, Cheng D, et al; American Heart Association Clinical Pharmacology and Heart Failure and Transplantation Committees of the Council on Clinical Cardiology; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular and Stroke Nursing; and Council on Quality of Care and Outcomes Research. Drugs That May Cause or Exacerbate Heart Failure: A Scientific Statement From the American Heart Association [published correction appears in <i>Circulation</i>. 2016;134(12):e261]. <i>Circulation</i>. 2016;134(6):e32-e69.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/propofol-drug-information/abstract-text/27400984/pubmed\" target=\"_blank\" id=\"27400984\">27400984</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"11442156\"></a>Prasad A, Worrall BB, Bertram EH, Bleck TP. Propofol and midazolam in the treatment of refractory status epilepticus. <i>Epileps</i>ia. 2001;42(3):380&ndash;386.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/propofol-drug-information/abstract-text/11442156/pubmed\" target=\"_blank\" id=\"11442156\">11442156</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"15230698\"></a>Rossetti AO, Reichhart MD, Schaller MD, et al, &ldquo;Propofol Treatment of Refractory Status Epilepticus: A Study of 31 Episodes,&rdquo; <i>Epilepsia,</i> 2004, 45(7):757-63.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/propofol-drug-information/abstract-text/15230698/pubmed\" target=\"_blank\" id=\"15230698\">15230698</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Saarnivaara L, Hiller A, Oikkonen M. QT interval, heart rate and arterial pressures using propofol, thiopentone or methohexitone for induction of anaesthesia in children. <i>Acta Anaesthesiol Scand</i>. 1993;37(4):419-423.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/propofol-drug-information/abstract-text/8322572/pubmed\" target=\"_blank\" id=\"8322572\">8322572</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Saarnivaara L, Klemola UM, Lindgren L, Rautiainen P, Suvanto A. QT interval of the ECG, heart rate and arterial pressure using propofol, methohexital or midazolam for induction of anaesthesia. <i>Acta Anaesthesiol Scand</i>. 1990;34(4):276-281.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/propofol-drug-information/abstract-text/2343728/pubmed\" target=\"_blank\" id=\"2343728\">2343728</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sakabe M, Fujiki A, Inoue H. Propofol induced marked prolongation of QT interval in a patient with acute myocardial infarction. <i>Anesthesiology</i>. 2002;97(1):265-266.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/propofol-drug-information/abstract-text/12131130/pubmed\" target=\"_blank\" id=\"12131130\">12131130</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shapiro BA, Warren J, Egol AB, et al, &ldquo;Practice Parameters for Intravenous Analgesia and Sedation for Adult Patients in the Intensive Care Unit: An Executive Summary. Society of Critical Care Medicine, <i>Crit Care Med</i>, 1995, 23(9):1596-600.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Short TG and Young Y, &ldquo;Toxicity of Intravenous Anaesthetics,&rdquo; <i>Best Pract Res Clin Anaesthesiol</i>, 2003, 17(1):77-89.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/propofol-drug-information/abstract-text/12751550/pubmed\" target=\"_blank\" id=\"12751550\">12751550</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Staikou C, Stamelos M, Stavroulakis E. Impact of anaesthetic drugs and adjuvants on ECG markers of torsadogenicity. <i>Br J Anaesth</i>. 2014;112(2):217-230.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/propofol-drug-information/abstract-text/24305646/pubmed\" target=\"_blank\" id=\"24305646\">24305646</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"9578008\"></a>Stecker MM, Kramer TH, Raps EC, O'Meeghan R, Dulaney E, Skaar DJ. Treatment of refractory status epilepticus with propofol: clinical and pharmacokinetic findings. <i>Epilepsia</i>. 1998;39(1):18&ndash;26.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/propofol-drug-information/abstract-text/9578008/pubmed\" target=\"_blank\" id=\"9578008\">9578008</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tanskanen PE, Kytt&auml; JV, Randell TT. QT interval and QT dispersion during the induction of anaesthesia in patients with subarachnoid haemorrhage: a comparison of thiopental and propofol. <i>Eur J Anaesthesiol</i>. 2002;19(10):749-754.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/propofol-drug-information/abstract-text/12463387/pubmed\" target=\"_blank\" id=\"12463387\">12463387</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Training Committee, American Society for Gastrointestinal Endoscopy, &ldquo;Training Guideline for Use of Propofol in Gastrointestinal Endoscopy,&rdquo; <i>Gastrointest Endosc</i>, 2004, 60(2):167-72.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/propofol-drug-information/abstract-text/15278039/pubmed\" target=\"_blank\" id=\"15278039\">15278039</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Food and Drug Administration. <i>FDA Drug Safety Communication: FDA review results in new warnings about using general anesthetics and sedation drugs in young children and pregnant women</i>. US Food and Drug Administration Web site. <a href=\"https://www.fda.gov/Drugs/DrugSafety/ucm554634.htm\" target=\"_blank\">https://www.fda.gov/Drugs/DrugSafety/ucm554634.htm</a>. Updated April 27, 2017. Accessed May 26, 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"16116121\"></a>van Gestel JP, Bluss&eacute; van Oud-Alblas HJ, Malingr&eacute; M, Ververs FF, Braun KP, van Nieuwenhuizen O. Propofol and thiopental for refractory status epilepticus in children. <i>Neurology</i>. 2005;65(4):591&ndash;592.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/propofol-drug-information/abstract-text/16116121/pubmed\" target=\"_blank\" id=\"16116121\">16116121</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9826 Version 214.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F214584\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F214585\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F214628\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F214588\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F214606\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F214589\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F13135189\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F13135190\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F214558\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F214542\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F214560\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F214559\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F27235450\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F214636\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F214549\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F214563\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F214546\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F214621\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F214551\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F214579\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F214566\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F20619295\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F214567\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F214556\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F214545\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F214562\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323734\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F214568\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9826|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=propofol-patient-drug-information\" class=\"drug drug_patient\">Propofol: Patient drug information</a></li><li><a href=\"topic.htm?path=propofol-pediatric-drug-information\" class=\"drug drug_pediatric\">Propofol: Pediatric drug information</a></li></ul></div></div>","javascript":null}